# A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

> **NCT07043725** · PHASE3 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 544 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** TQB2102 for injection
- **DRUG:** Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection

## Key facts

- **NCT ID:** NCT07043725
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2027-09
- **Final completion:** 2029-09
- **Target enrollment:** 544 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07043725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07043725, "A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07043725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*